EZR and cancer: Thus, our proposed model of ezrin-mediated activation of SOS now allows us to conceive how such inappropriate activation of co-receptors, e.g. mis-expression of the co-receptor CD44v6 for the RTK c-Met [39], as well as elevated expression of ezrin [37], radixin [38] and moesin [36] may contribute to cancer progression and metastasis.